2017


To access this material please log in or register

Register Authorize
2017/№1

Clinical guidelines. Chronic heart failure (CHF)

Mareev V. Yu.1, Fomin I. V.2, Ageev F. T.3, Arutyunov G. P.4, Begrambekova Yu. L.1, Belenkov Yu. N.5, Vasyuk Yu. A.6, Galyavich A. S.7, Garganeeva A. A.8, Gendlin G. E.4, Gilyarevsky S. R.9, Glezer M. G.5, Drapkina O. M.10, Duplyakov D. V.11, Kobalava Zh. D.12, Koziolova N. A.13, Lopatin Yu. M.14, Mareev Yu. V.3, Moiseev V. S.12, Nedoshivin A. O.15, Perepech N. B.16, Sitnikova M. Yu.15, Skibitsky V. V.17, Tarlovskaya E. I.2, Chesnikova A. I.18, Shlyakhto E. V.15
1 – Federal State Budgetary Educational Institution of Higher Education,
"M. V. Lomonosov Moscow State University", Leninskie Gory 1, GSP-1, Moscow 119991
2 – Federal State Budgetary Educational Institution of Higher Education, "Nizhny Novgorod State Medical Academy"
of the Ministry of Health of the Russian Federation, pl. Minina i Pozharskogo 10/1, Nizhny Novgorod 603005
3 – Federal State Budgetary Institution, "Russian Cardiology Science and Production Center"
of the Ministry of Health of the Russian Federation, 3rd Cherepkovskaya 15a, Moscow 121552
4 – Federal State Budgetary Educational Institution of Higher Education, "Pirogov Russian National
Research Medical University" of the Ministry of Health of the Russian Federation, Ostrovityanova 1, Moscow 117997
5 – Federal State Budgetary Educational Institution of Higher Education "I. M. Sechenov First Moscow State
Medical University" of the Ministry of Health of the Russian Federation, Trubetskaya 8, Bldg. 2, Moscow 119991
6 – Federal State Budgetary Educational Institution of Higher Education, "A. I. Evdokimov Moscow State University for Medicine
and Dentistry" of the Ministry of Health of the Russian Federation, Delegatskaya 20, Bld. 1, Moscow 127473
7 – Federal State Budget Educational Institution of Higher Education, "Kazan State Medical University"
of the Ministry of Health of the Russian Federation, Butlerova 49, Kazan 420012
8 – Federal State Budgetary Science Institution "Tomsk Research Institute of Cardiology
of the Siberian Branch of the Russian Academy of Science", Kievskaya 111a, Tomsk 634012
9 – State Budgetary Educational Institution of Advanced Professional Education, "Russian Medical Academy
of Postgraduate Education" of the Ministry of Health of the Russian Federation, Barrikadnaya 2/1, Moscow 123995
10 – State Budgetary Institution of Health Care "National Research Center for Preventive Medicine"
of the Ministry of Health of the Russian Federation, Petroverigsky Per. 10, Bldg. 3, Moscow 101990
11 – State Budgetary Educational Institution, "Samara Regional Clinical Cardiology Center", Aerodromnaya 43, Samara 443070
12 – Federal State Autonomous Educational Institution of Higher Education,
"Peoples' Friendship University of Russia", Miklukho-Maklaya str. 6, Moscow, Russia 117198
13 – Federal State Budgetary Educational Institution of Higher Education, "Academician E. A. Vagner Perm State
Medical Academy" of the Ministry of Health of the Russian Federation, Petropavlovskaya 26, Perm 614000
14 – Federal State Budgetary Educational Institution of Higher Education "Volgograd State Medical University"
of the Ministry of Health of the Russian Federation, pl. Pavshikh Bortsov 1, Volgograd 400131
15 – Federal State Budgetary Institution "Federal Almazov North-West Medical Research Center"
of the Ministry of Health of the Russian Federation, Akkuratova 2, St. Petersburg 197341
16 – Federal State Budgetary Educational Institution of Higher Education
"Saint-Petersburg State University", 7/9 University Embankment, St.-Petersburg, 199034
17 – Federal State Budgetary Educational Institution of Higher Education "Kuban State Medical University"
of the Ministry of Health of the Russian Federation, Sedina str. 4, Krasnodar, Russia 350063
18 – Federal State Budgetary Educational Institution of Higher Education "Rostov State Medical University"
of the Ministry of Health of the Russian Federation, Nahichevansky av. 29, Rostov-on-Don 344022

Keywords: guidelines, heart failure, myocardium, left ventricular ejection fraction, functional class of heart failure, acute decompensated heart failure, ACE inhibitors, beta-adrenergic blocker agents, mineralocorticoid receptor antagonists, diuretics, physical exercises

DOI: 10.18087/rhfj.2017.1.2346

  1. Фомин И. В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016; (8):7–13. DOI:10.15829/1560-4071-2016-8-7-13 [Fomin I. V. Xronicheskaya serdechnaya nedostatochnost` v Rossijskoj Federaczii: chto segodnya my` znaem i chto dolzhny` delat`. Rossijskij kardiologicheskij zhurnal. 2016; (8):7–13. DOI:10.15829/1560-4071-2016-8-7-13].
  2. Беленков Ю. Н., Фомин И. В., Мареев В. Ю., Агеев Ф. Т., Бадин Ю. В., Галявич А. С. и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации данные ЭПОХА–ХСН (часть 2). Журнал Сердечная Недостаточность. 2006;7 (3):3–7 [Belenkov Yu. N., Fomin I. V., Mareev V. Yu., Ageev F. T., Badin Yu. V., Galyavich A. S. i dr. Rasprostranennost` xronicheskoj serdechnoj nedostatochnosti v Evropejskoj chasti Rossijskoj Federaczii danny`e E`POXA–XSN (chast` 2). Zhurnal Serdechnaya Nedostatochnost`. 2006;7 (3):3–7].
  3. Фомин И. В. Эпидемиология хронической сердечной недостаточности в Российской Федерации. В: Хроническая сердечная недостаточность. –М.: ГЭОТАР-Медиа; 2010. с. 7–77 [Fomin I. V. E`pidemiologiya xronicheskoj serdechnoj nedostatochnosti v Rossijskoj Federaczii. V: Xronicheskaya serdechnaya nedostatochnost`. –M.: GE`OTAR-Media; 2010. s. 7–77].
  4. Поляков Д. С., Фомин И. В., Валикулова Ф. Ю., Вайсберг А. Р., Краием Н., Бадин Ю. В. и др. Эпидемиологическая программа ЭПОХА–ХСН: декомпенсация хронической сердечной недостаточности в реальной клинической практике (ЭПОХА–Д–ХСН). Журнал Сердечная Недостаточность. 2016;17 (6):299–305. DOI:10.18087/rhfj.2016.5.2239 [Polyakov D. S., Fomin I. V., Valikulova F. Yu., Vajsberg A. R., Kraiem N., Badin Yu. V. i dr. E`pidemiologicheskaya programma E`POXA–XSN: dekompensacziya xronicheskoj serdechnoj nedostatochnosti v real`noj klinicheskoj praktike (E`POXA–D–XSN). Zhurnal Serdechnaya Nedostatochnost`. 2016;17 (6):299–305. DOI:10.18087/rhfj.2016.5.2239].
  5. Козиолова Н. А., Никонова Ю. Н., Шилова Я. Э., Агафонов А. В., Полянская Е. А. Характеристика хронической сердечной недостаточности на фоне перманентной формы фибрилляции предсердий. Журнал Сердечная Недостаточность. 2013;14 (1):14–21. DOI:10.18087/rhfj.2013.1.1806 [Koziolova N. A., Nikonova Yu. N., Shilova Ya. E`., Agafonov A. V., Polyanskaya E. A. Xarakteristika xronicheskoj serdechnoj nedostatochnosti na fone permanentnoj formy` fibrillyaczii predserdij. Zhurnal Serdechnaya Nedostatochnost`. 2013;14 (1):14–21. DOI:10.18087/rhfj.2013.1.1806].
  6. Фомин И. В., Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т., Бадин Ю. В., Галявич А. С. и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации – данные ЭПОХА–ХСН. Журнал Сердечная Недостаточность. 2006;7 (3):112–5 [Fomin I. V., Belenkov Yu. N., Mareev V. Yu., Ageev F. T., Badin Yu. V., Galyavich A. S. i dr. Rasprostranennost` xronicheskoj serdechnoj nedostatochnosti v Evropejskoj chasti Rossijskoj Federaczii – danny`e E`POXA–XSN. Zhurnal Serdechnaya Nedostatochnost`. 2006;7 (3):112–5].
  7. Артемьева Е. Г., Маленкова В. Ю., Фролова Е. В. Распростра­ненность артериальной гипертензии при хронической сердечной недостаточности в Чувашской Республике. Медицинский альманах. 2011; (16):51–4 [Artem`eva E. G., Malenkova V. Yu., Frolova E. V. Rasprostranennost` arterial`noj gipertenzii pri xronicheskoj serdechnoj nedostatochnosti v Chuvashskoj Respublike. Mediczinskij al`manax. 2011; (16):51–4]
  8. Сергеева Е. М., Малишевский М. В., Васина А. А., Мищенко Т. А., Кузьмина Ю. С., Раемгулов Р. А. Лечение хронической сердечной недостаточности в первичном звене муниципального здравоохранения в г. Тюмени. Медицинская наука и образование Урала. 2015;16 (4):32–4 [Sergeeva E. M., Malishevskij M. V., Vasina A. A., Mishhenko T. A., Kuz`mina Yu. S., Raemgulov R. A. Lechenie xronicheskoj serdechnoj nedostatochnosti v pervichnom zvene municzipal`nogo zdravooxraneniya v g. Tyumeni. Mediczinskaya nauka i obrazovanie Urala. 2015;16 (4):32–4].
  9. Шакирова Р. М., Галявич А. С., Камалов Г. М. Распространенность сердечно-сосудистых заболеваний и сахарного диабета в республике Татарстан и их взаимосвязь с симптомами хронической сердечной недостаточности. Журнал Сердечная Недостаточность. 2005;6 (2):72–3 [Shakirova R. M., Galyavich A. S., Kamalov G. M. Rasprostranennost` serdechno-sosudisty`x zabolevanij i saxarnogo diabeta v respublike Tatarstan i ix vzaimosvyaz` s simptomami xronicheskoj serdechnoj nedostatochnosti. Zhurnal Serdechnaya Nedostatochnost`. 2005;6 (2):72–3].
  10. Смирнова Е. А. Изучение распространенности и этиологии хронической сердечной недостаточности в Рязанской области. Российский кардиологический журнал. 2010; (2):78–83 [Smirnova E. A. Izuchenie rasprostranennosti i e`tiologii xronicheskoj serdechnoj nedostatochnosti v Ryazanskoj oblasti. Rossijskij kardiologicheskij zhurnal. 2010; (2):78–83].
  11. Бабанская Е. Б., Меньшикова Л. В., Дац Л. С. Эпидемио­ло­гия хронической сердечной недостаточности в городе Иркутске. Бюллетень ВСНЦ СО РАМН. 2012; (5–1):25–8 [Babanskaya E. B., Men`shikova L. V., Dacz L. S. E`pidemiologiya xronicheskoj serdechnoj nedostatochnosti v gorode irkutske. Byulleten` VSNCz SO RAMN. 2012; (5–1):25–8].
  12. Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т., Фомин И. В., Бадин Ю. В., Поляков Д. С. и др. Истинная распространенность ХСН в Европейской части Российской Федерации (исследование ЭПОХА, госпитальный этап). Журнал Сердечная Недостаточность. 2011;12 (2):63–8 [Belenkov Yu. N., Mareev V. Yu., Ageev F. T., Fomin I. V., Badin Yu. V., Polyakov D. S. i dr. Istinnaya rasprostranennost` XSN v Evropejskoj chasti Rossijskoj Federaczii (issledovanie E`POXA, gospital`ny`j e`tap). Zhurnal Serdechnaya Nedostatochnost`. 2011;12 (2):63–8].
  13. Беленков Ю. Н., Фомин И. В., Мареев В. Ю., Агеев Ф. Т., Бадин Ю. В., Галявич А. С. и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации данные ЭПОХА–ХСН (часть 2). Журнал Сердечная Недостаточность. 2006;7 (3):3–7 [Belenkov Yu. N., Fomin I. V., Mareev V. Yu., Ageev F. T., Badin Yu. V., Galyavich A. S. i dr. Rasprostranennost` xronicheskoj serdechnoj nedostatochnosti v Evropejskoj chasti Rossijskoj Federaczii danny`e E`POXA–XSN (chast` 2). Zhurnal Serdechnaya Nedostatochnost`. 2006;7 (3):3–7]
  14. Фомин И. В., Бадин Ю. В., Поляков Д. С., Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т. и др. Предгипертония: как часто встречается данное состояние сердечно-сосудистой системы у граждан Европейской части России (данные исследования ЭПОХА–АГ, 2002–2007 гг.). Современные технологии в медицине. 2013;5 (2):38–46 [Fomin I. V., Badin Yu. V., Polyakov D. S., Belenkov Yu. N., Mareev V. Yu., Ageev F. T. i dr. Predgipertoniya: kak chasto vstrechaetsya dannoe sostoyanie serdechno-sosudistoj sistemy` u grazhdan Evropejskoj chasti Rossii (danny`e issledovaniya E`POXA–AG, 2002–2007 gg.). Sovremenny`e texnologii v mediczine. 2013;5 (2):38–46].
  15. Fuat A, Murphy JJ, Hungin APS, Curry J, Mehrzad AA, Hetherington A et al. The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract. 2006;56 (526):327–33.
  16. Yamamoto K, Burnett JC, Bermudez EA, Jougasaki M, Bailey KR, Redfield MM. Clinical criteria and biochemical markers for the detection of systolic dysfunction. Journal of Cardiac Failure. 2000;6 (3):194–200. DOI:10.1054/jcaf.2000.9676.
  17. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. The Lancet. 1997;350 (9088):1349–53. DOI:10.1016/S0140–6736 (97) 06031–5.
  18. Krishnaswamy P, Lubien E, Clopton P, Koon J, Kazanegra R, Wanner E et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med. 2001;111 (4):274–9.
  19. Kelder JC, Cowie MR, McDonagh TA, Hardman SMC, Grobbee DE, Cost B et al. Quantifying the added value of BNP in suspected heart failure in general practice: an indivi­dual patient data meta-analysis. Heart. 2011;97 (12):959–63. DOI:10.1136/hrt.2010.220426.
  20. Kelder JC, Cramer MJ, Verweij WM, Grobbee DE, Hoes AW. Clinical Utility of Three B-Type Natriuretic Peptide Assays for the Initial Diagnostic Assessment of New Slow-Onset Heart Failure. Journal of Cardiac Failure. 2011;17 (9):729–34. DOI:10.1016/j.cardfail.2011.04.013.
  21. Gustafsson F, Steensgaard-Hansen F, Badskjaer J, Poulsen AH, Corell P, Hildebrandt P. Diagnostic and prognostic performance of N-terminal ProBNP in primary care patients with suspected heart failure. J Card Fail. 2005;11 (5 Suppl): S15–20.
  22. Nielsen OW, Rasmussen V, Christensen NJ, Hansen JF. Neuro­endocrine testing in community patients with heart disease: plasma N-terminal proatrial natriuretic peptide predicts morbidity and mortality stronger than catecholamines and heart rate variabi­lity. Scandinavian Journal of Clinical and Laboratory Investigation. 2004;64 (7):619–28. DOI:10.1080/00365510410002878.
  23. Sicari R, Nihoyannopoulos P, Evangelista A, Kasprzak J, Lancellotti P, Poldermans D et al. Stress Echocardiography Expert Consensus Statement – Executive Summary: European Association of Echocardiography (EAE) (a registered branch of the ESC). European Heart Journal. 2008;30 (3):278–89. DOI:10.1093/eurheartj/ehn492.
  24. Beller GA, Heede RC. SPECT Imaging for Detecting Coronary Artery Disease and Determining Prognosis by Noninvasive Assessment of Myocardial Perfusion and Myocardial Viability. Journal of Cardiovascular Translational Research. 2011;4 (4):416–24. DOI:10.1007/s12265‑011‑9290‑2.
  25. Sheikine Y, Di Carli MF. Integrated PET/CT in the assessment of etiology and viability in ischemic heart failure. Curr Heart Fail Rep. 2008;5 (3):136–42
  26. Beanlands RSB, Nichol G, Huszti E, Humen D, Racine N, Freeman M et al. F-18‑Fluorodeoxyglucose Positron Emission Tomography Imaging-Assisted Management of Patients With Severe Left Ventricular Dysfunction and Suspected Coronary Disease. Journal of the American College of Cardiology. 2007;50 (20):2002–12. DOI:10.1016/j.jacc.2007.09.006.
  27. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002;39 (7):1151–8.
  28. Ling LF, Marwick TH, Flores DR, Jaber WA, Brunken RC, Cerqueira MD et al. Identification of Therapeutic Benefit from Revascularization in Patients With Left Ventricular Systolic Dysfunction: Inducible Ischemia Versus Hibernating Myocardium. Circulation: Cardiovascular Imaging. 2013;6 (3):363–72. DOI:10.1161/CIRCIMAGING.112.000138.
  29. Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P et al. Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction. New England Journal of Medicine. 2011;364 (17):1617–25. DOI:10.1056/NEJMoa1100358.
  30. Arena R, Myers J, Guazzi M. Cardiopulmonary Exercise Testing Is a Core Assessment for Patients With Heart Failure. Congestive Heart Failure. 2011;17 (3):115–9. DOI:10.1111/j.1751–7133.2011.00216.
  31. Мареев Ю. В., Герасимова В. В., Горюнова Т. В., Петрухина А. А., Даниелян М. О., Капанадзе Л. Г. и др. Факторы, определяющие прогноз при хронической сердечной недостаточности: роль ширины и морфологии комплекса QRS. Журнал Сердечная Недостаточность. 2012;13 (5):255–66 [Mareev Yu. V., Gerasimova V. V., Goryunova T. V., Petruxina A. A., Danielyan M. O., Kapanadze L. G. i dr. Faktory`, opredelyayushhie prognoz pri xronicheskoj serdechnoj nedostatochnosti: rol` shiriny` i morfologii kompleksa QRS. Zhurnal Serdechnaya Nedostatochnost`. 2012;13 (5):255–66].
  32. Bergström A, Andersson B, Edner M, Nylander E, Persson H, Dahlström U. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). European Journal of Heart Failure. 2004;6 (4):453–61. DOI:10.1016/j.ejheart.2004.02.003.
  33. Flather MD. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal. 2004;26 (3):215–25. DOI:10.1093/eurheartj/ehi115.
  34. Беленков Ю. Н., Мареев В. Ю. Лечение сердечной недостаточности в XXI веке: достижения, вопросы и уроки доказательной медицины. Кардиология. 2008;48 (2):6–16 [Belenkov Yu. N., Mareev V. Yu. Lechenie serdechnoj nedostatochnosti v XXI veke: dostizheniya, voprosy` i uroki dokazatel`noj medicziny`. Kardiologiya. 2008;48 (2):6–16].
  35. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289 (7):871–8.
  36. Gheorghiade M, Patel K, Filippatos G, Anker SD, van Veldhuisen DJ, Cleland JGF et al. Effect of oral digoxin in high-risk heart fai­lure patients: a pre-specified subgroup analysis of the DIG trial. European Journal of Heart Failure. 2013;15 (5):551–9. DOI:10.1093/eurjhf/hft010.
  37. Packer M, Carson P, Elkayam U, Konstam MA, Moe G, O’Connor C et al. Effect of Amlodipine on the Survival of Patients With Severe Chronic Heart Failure Due to a Nonischemic Cardiomyopathy. JACC: Heart Failure. 2013;1 (4):308–14. DOI:10.1016/j.jchf.2013.04.004.
  38. Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation. 1997;96 (3):856–63.
  39. Anker SD, Colet JC, Filippatos G, Willenheimer R, Dickstein K, Drexler H et al. Rationale and design of Ferinject® Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. European Journal of Heart Failure. 2009;11 (11):1084–91. DOI:10.1093/eurjhf/hfp140.
  40. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. European Heart Journal. 2015;36 (11):657–68. DOI:10.1093/eurheartj/ehu385.
  41. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JGF, Cornel JH et al. Rosuvastatin in Older Patients with Systolic Heart Failure. New England Journal of Medicine. 2007;357 (22):2248–61. DOI:10.1056/NEJMoa0706201.
  42. Wang J-Q, Wu G-R, Wang Z, Dai X-P, Li X-R. Long-term Clinical Outcomes of Statin Use for Chronic Heart Failure: A Meta-analysis of 15 Prospective Studies. Heart, Lung and Circulation. 2014;23 (2):105–13. DOI:10.1016/j.hlc.2013.07.012.
  43. Fotino AD, Thompson-Paul AM, Bazzano LA. Effect of coenzyme Q 10 supplementation on heart failure: a meta-analysis. American Journal of Clinical Nutrition. 2013;97 (2):268–75. DOI:10.3945/ajcn.112.040741.
  44. Мареев В. Ю., Минина Ю. В., Беграмбекова Ю. Л. КУДЕсан® (капли 3 % для приема внутрь) в лечении больных Сердечной Недостаточностью: эффективность И безопасность в Комбинации со стандартной терапией (КУДЕСНИК). Дизайн и результаты проспективного рандомизированного двойного слепого исследования КУДЕСНИК. Журнал Сердечная Недостаточность. 2016;17 (4):236–49. DOI:10.18087/rhfj.2016.4.2257 [Mareev V. Yu., Minina Yu. V., Begrambekova Yu. L. KUDEsan® (kapli 3 % dlya priema vnutr`) v lechenii bol`ny`x Serdechnoj Nedostatochnost`yu: e`ffektivnost` I bezopasnost` v Kombinaczii so standartnoj terapiej (KUDESNIK). Dizajn i rezul`taty` prospektivnogo randomizirovannogo dvojnogo slepogo issledovaniya KUDESNIK. Zhurnal Serdechnaya Nedostatochnost`. 2016;17 (4):236–49. DOI:10.18087/rhfj.2016.4.2257].
  45. Mortensen SA, Rosenfeldt F, Kumar A, Dolliner P, Filipiak KJ, Pella D et al. The Effect of Coenzyme Q 10 on Morbidity and Mortality in Chronic Heart Failure. JACC: Heart Failure. 2014;2 (6):641–9. DOI:10.1016/j.jchf.2014.06.008.
  46. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A et al. Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction. New England Journal of Medicine. 2011;364 (17):1607–16. DOI:10.1056/NEJMoa1100356.
  47. Bangalore S, Pursnani S, Kumar S, Bagos PG. Percutaneous Coronary Intervention Versus Optimal Medical Therapy for Prevention of Spontaneous Myocardial Infarction in Subjects With Stable Ischemic Heart Disease. Circulation. 2013;127 (7):769–81. DOI:10.1161/CIRCULATIONAHA.112.131961.
  48. Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK, Kent DM. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20‑year synopsis and a network meta-analysis. The Lancet. 2009;373 (9667):911–8. DOI:10.1016/S0140–6736 (09) 60319–6.
  49. Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA et al. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. New England Journal of Medicine. 2016;374 (16):1511–20. DOI:10.1056/NEJMoa1602001.
  50. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37 (27):2129–200. DOI:10.1093/eurheartj/ehw128
  51. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease. Journal of the American College of Cardiology. 2014;63 (22):e57–185. DOI:10.1016/j.jacc.2014.02.536.
  52. Latib A, Giannini A. Cardiac Interventions Today – The Next Frontier of Percutaneous Tricuspid Valve Repair. Cardiac Interventions Today. 2016;10 (4):54–9.
  53. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W et al. Long-Term Use of a Left Ventricular Assist Device for End-Stage Heart Failure. New England Journal of Medicine. 2001;345 (20):1435–43. DOI:10.1056/NEJMoa012175.
  54. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D et al. Advanced Heart Failure Treated with Continuous-Flow Left Ventricular Assist Device. New England Journal of Medicine. 2009;361 (23):2241–51. DOI:10.1056/NEJMoa0909938.
  55. Estep JD, Starling RC, Horstmanshof DA, Milano CA, Selzman CH, Shah KB et al. Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients. Journal of the American College of Cardiology. 2015;66 (16):1747–61. DOI:10.1016/j.jacc.2015.07.075.
  56. Sipahi I, Chou JC, Hyden M, Rowland DY, Simon DI, Fang JC. Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: Meta-analysis of randomized controlled trials. American Heart Journal. 2012;163 (2):260–267.e3. DOI:10.1016/j.ahj.2011.11.014.
  57. Cleland JG, Abraham WT, Linde C, Gold MR, Young JB, Claude Daubert J et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with sympto­matic heart failure. European Heart Journal. 2013;34 (46):3547–56. DOI:10.1093/eurheartj/eht290.
  58. Kang S-H, Oh I-Y, Kang D-Y, Cha M-J, Cho Y, Choi E-K et al. Cardiac Resynchronization Therapy and QRS Duration: Systematic Review, Meta-analysis, and Meta-regression. Journal of Korean Medical Science. 2015;30 (1):24. DOI:10.3346/jkms.2015.30.1.24.
  59. Birnie DH, Ha A, Higginson L, Sidhu K, Green M, Philippon F et al. Impact of QRS Morphology and Duration on Outcomes After Cardiac Resynchronization Therapy: Results From the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT). Circulation: Heart Failure. 2013;6 (6):1190–8. DOI:10.1161/CIRCHEARTFAILURE.113.000380.
  60. Gasparini M, Auricchio A, Metra M, Regoli F, Fantoni C, Lamp B et al. Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. European Heart Journal. 2008;29 (13):1644–52. DOI:10.1093/eurheartj/ehn133.
  61. Gasparini M, Leclercq C, Lunati M, Landolina M, Auricchio A, Santini M et al. Cardiac Resynchronization Therapy in Patients With Atrial Fibrillation. JACC: Heart Failure. 2013;1 (6):500–7. DOI:10.1016/j.jchf.2013.06.003.
  62. Delnoy PPHM, Ottervanger JP, Luttikhuis HO, Elvan A, Misier ARR, Beukema WP et al. Comparison of Usefulness of Cardiac Resynchronization Therapy in Patients With Atrial Fibrillation and Heart Failure Versus Patients With Sinus Rhythm and Heart Failure. The American Journal of Cardiology. 2007;99 (9):1252–7. DOI:10.1016/j.amjcard.2006.12.040.
  63. Healey JS, Hohnloser SH, Exner DV, Birnie DH, Parkash R, Connolly SJ et al. Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation: Results From the Resynchro­nization for Ambulatory Heart Failure Trial (RAFT). Circulation: Heart Failure. 2012;5 (5):566–70. DOI:10.1161/CIRCHEARTFAILURE.112.968867.
  64. Beshai JF, Grimm RA, Nagueh SF, Baker JH, Beau SL, Greenberg SM et al. Cardiac-Resynchronization Therapy in Heart Failure with Narrow QRS Complexes. New England Journal of Medicine. 2007;357 (24):2461–71. DOI:10.1056/NEJMoa0706695.
  65. on behalf of the ESTEEM–CRT Investigators, Donahue T, Niazi I, Leon A, Stucky M, Herrmann K. Acute and Chronic Response to CRT in Narrow QRS Patients. Journal of Cardiovascular Translational Research. 2012;5 (2):232–41. DOI:10.1007/s12265‑011‑9338‑3.
  66. Thibault B, Harel F, Ducharme A, White M, Ellenbogen KA, Frasure-Smith N et al. Cardiac Resynchronization Therapy in Patients With Heart Failure and a QRS Complex <120 Milliseconds: The Evaluation of Resynchronization Therapy for Heart Failure (LESSER-EARTH) Trial. Circulation. 2013;127 (8):873–81. DOI:10.1161/CIRCULATIONAHA.112.001239.
  67. Steffel J, Robertson M, Singh JP, Abraham WT, Bax JJ, Borer JS et al. The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. European Heart Journal. 2015;36 (30):1983–9. DOI:10.1093/eurheartj/ehv242.
  68. Connolly S. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. European Heart Journal. 2000;21 (24):2071–8. DOI:10.1053/euhj.2000.2476.
  69. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS et al. Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction. New England Journal of Medicine. 2002;346 (12):877–83. DOI:10.1056/NEJMoa013474.
  70. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al. Amiodarone or an Implantable Cardioverter – Defibrillator for Congestive Heart Failure. New England Journal of Medicine. 2005;352 (3):225–37. DOI:10.1056/NEJMoa043399.
  71. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable Defibrillators for the Prevention of Mortality in Patients With Nonischemic Cardiomyopathy: A Meta-analysis of Randomized Controlled Trials. JAMA. 2004;292 (23):2874. DOI:10.1001/jama.292.23.2874.
  72. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM et al. Wasting as independent risk factor for morta­lity in chronic heart failure. The Lancet. 1997;349 (9058):1050–3. DOI:10.1016/S0140–6736 (96) 07015–8.
  73. Anker SD, Coats AJ. Cachexia in heart failure is bad for you. Eur Heart J. 1998;19 (2):191–3.
  74. Pasini E, Aquilani R, Gheorghiade M, Dioguardi FS. Malnutrition, muscle wasting and cachexia in chronic heart failure: the nutritio­nal approach. Ital Heart J. 2003;4 (4):232–5.
  75. Heymsfield SB, Casper K. Congestive heart failure: clinical mana­gement by use of continuous nasoenteric feeding. Am J Clin Nutr. 1989;50 (3):539–44
  76. Paccagnella A, Calò MA, Caenaro G, Salandin V, Jus P, Simini G et al. Cardiac cachexia: preoperative and postoperative nutrition management. JPEN J Parenter Enteral Nutr. 1994;18 (5):409–16.
  77. Шестопалов А. Е., Матраева Ю. С., Дьяков А. Ю., Кожемяка И. В., Кудряшов С. К., Чернов М. Ю. Нутритивная поддержка и коррекция метаболических нарушений у больных с ишемической болезнью сердца и дефицитом тощей массы тела при хирургической реваскуляризации миокарда. Сердечная недостаточность. 2001;2 (3):108–12 [Shestopalov A. E., Matraeva Yu. S., D`yakov A. Yu., Kozhemyaka I. V., Kudryashov S. K., Chernov M. Yu. Nutritivnaya podderzhka i korrekcziya metabolicheskix narushenij u bol`ny`x s ishemicheskoj bolezn`yu serdcza i deficzitom toshhej massy` tela pri xirurgicheskoj revaskulyarizaczii miokarda. Serdechnaya nedostatochnost`. 2001;2 (3):108–12].
  78. Арутюнов Г. П., Костюкевич О. И. Питание больных с хронической сердечной недостаточностью, проблемы нутритивной поддержки, решенные и нерешенные аспекты. Журнал Сердечная Недостаточность. 2002;3 (5):245–8 [Arutyunov G. P., Kostyukevich O. I. Pitanie bol`ny`x s xronicheskoj serdechnoj nedostatochnost`yu, problemy` nutritivnoj podderzhki, reshenny`e i nereshenny`e aspekty`. Zhurnal Serdechnaya Nedostatochnost`. 2002;3 (5):245–8].
  79. Walsh CR, Larson MG, Evans JC, Djousse L, Ellison RC, Vasan RS et al. Alcohol consumption and risk for congestive heart fai­lure in the Framingham Heart Study. Ann Intern Med. 2002;136 (3):181–91.
  80. Abramson JL, Williams SA, Krumholz HM, Vaccarino V. Moderate alcohol consumption and risk of heart failure among older persons. JAMA. 2001;285 (15):1971–7.
  81. Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. New England Journal of Medicine. 2016;375 (13):1221–30. DOI:10.1056/NEJMoa1608029.
  82. Sullivan MJ, Higginbotham MB, Cobb FR. Exercise training in patients with chronic heart failure delays ventilatory anaerobic threshold and improves submaximal exercise performance. Circulation. 1989;79 (2):324–9. DOI:10.1161/01. CIR.79.2.324.
  83. Smart N, Marwick TH. Exercise training for patients with heart failure: a systematic review of factors that improve mortality and morbidity. The American Journal of Medicine. 2004;116 (10):693–706. DOI:10.1016/j.amjmed.2003.11.033.
  84. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ. 2004;328 (7433):189–0. DOI:10.1136/bmj.37938.645220. EE.
  85. Isnard R, Pousset F, Trochu J-N, Chafirovskaïa O, Carayon A, Golmard J-L et al. Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure. The American Journal of Cardiology. 2000;86 (4):417–21. DOI:10.1016/S0002–9149 (00) 00957–7.
  86. Guazzi M, Adams V, Conraads V, Halle M, Mezzani A, Vanhees L et al. Clinical Recommendations for Cardiopulmonary Exercise Testing Data Assessment in Specific Patient Populations. Circulation. 2012;126 (18):2261–74. DOI:10.1161/CIR.0b013e31826fb946.
  87. Арутюнов Г. П. Вопросы немедикаментозного лечения пациентов, страдающих сердечной недостаточностью. Сердечная недостаточность. 2001;2 (1):35–6 [Arutyunov G. P. Voprosy` nemedikamentoznogo lecheniya paczientov, stradayushhix serdechnoj nedostatochnost`yu. Serdechnaya nedostatochnost`. 2001;2 (1):35–6].
  88. Осипова И. В. «Свободный выбор нагрузки» физических тренировок – эффективный метод лечения хронической сердечной недостаточности. Сердечная недостаточность. 2001;2 (4):176–80 [Osipova I. V. «Svobodny`j vy`bor nagruzki» fizicheskix trenirovok – e`ffektivny`j metod lecheniya xronicheskoj serdechnoj nedostatochnosti. Serdechnaya nedostatochnost`. 2001;2 (4):176–80].
  89. Оганов Р. Г., Кухарчук В. В., Арутюнов Г. П., Галявич А. С., Гуревич В. С., Дупляков Д. В. и др. Сохраняющиеся нарушения показателей липидного спектра у пациентов с дислипидемией, получающих статины, в реальной клинической практике в Российской Федерации (российская часть исследования DYSIS). Кардиоваскулярная терапия и профилактика. 2012;11 (4):70–8 [Oganov R. G., Kuxarchuk V. V., Arutyunov G. P., Galyavich A. S., Gurevich V. S., Duplyakov D. V. i dr. Soxranya­yushhiesya narusheniya pokazatelej lipidnogo spektra u paczientov s dislipidemiej, poluchayushhix statiny`, v real`noj klinicheskoj praktike v Rossijskoj Federaczii (rossijskaya chast` issledovaniya DYSIS). Kardiovaskulyarnaya terapiya i profilaktika. 2012;11 (4):70–8].
  90. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyörälä K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997;3 (4):249–54.
  91. Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med. 1998;129 (9):681–9.
  92. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339 (19):1349–57. DOI:10.1056/NEJM199811053391902.
  93. The Norwegian Multicenter Study Group. Timolol-Induced Reduction in Mortality and Reinfarction in Patients Surviving Acute Myocardial Infarction. New England Journal of Medicine. 1981;304 (14):801–7. DOI:10.1056/NEJM198104023041401.
  94. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation. 1986;73 (3):503–10.
  95. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE et al. Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction: Results of the Survival and Ventricular Enlargement Trial. New England Journal of Medicine. 1992;327 (10):669–77. DOI:10.1056/NEJM199209033271001.
  96. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6‑week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. Lancet. 1994;343 (8906):1115–22.
  97. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995;345 (8951):669–85.
  98. Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau J-L, Køber L, Maggioni AP et al. Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. New England Journal of Medicine. 2003;349 (20):1893–906. DOI:10.1056/NEJMoa032292.
  99. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. New England Journal of Medicine. 2003;348 (14):1309–21. DOI:10.1056/NEJMoa030207.
  100. Vantrimpont P, Rouleau JL, Wun C–C, Ciampi A, Klein M, Sussex B et al. Additive Beneficial Effects of Beta-Blockers to Angiotensin-Converting Enzyme Inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. Journal of the American College of Cardiology. 1997;29 (2):229–36. DOI:10.1016/S0735–1097(96)00489–5.
  101. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275 (20):1557–62
  102. Мареев В. Ю., Беленков Ю. Н. Хроническая сердечная недостаточность и инсулиннезависимый сахарный диабет случайная связь или закономерность. Терапевтический архив. 2003;75 (10):1–10 [Mareev V. Yu., Belenkov Yu. N. Xronicheskaya serdechnaya nedostatochnost` i insulinnezavisimy`j saxarny`j diabet sluchajnaya svyaz` ili zakonomernost`. Terapevticheskij arxiv. 2003;75 (10):1–10].
  103. Ильина А. В., Мареев В. Ю., Герасимова В. В., Джахангиров Т. Ш., Беленков Ю. Н. Эффективность терапии иАПФ фозиноприлом больных с ХСН в сочетании с СД 2 типа (по материалам исследования ФАСОН). Журнал Сердечная Недостаточность. 2005;6 (5):181–5 [Il`ina A. V., Mareev V. Yu., Gerasimova V. V., Dzhaxangirov T. Sh., Belenkov Yu. N. E`ffektivnost` terapii iAPF fozinoprilom bol`ny`x s XSN v sochetanii s SD 2 tipa (po materialam issledovaniya FASON). Zhurnal Serdechnaya Nedostatochnost`. 2005;6 (5):181–5].
  104. Krumholz HM, Chen YT, Wang Y, Vaccarino V, Radford MJ, Horwitz RI. Predictors of readmission among elderly survivors of admission with heart failure. Am Heart J. 2000;139 (1 Pt 1):72–7.
  105. Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol. 1996;77 (11):1017–20.
  106. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317 (7160):703–13.
  107. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy. New England Journal of Medicine. 1993;329 (20):1456–62. DOI:10.1056/NEJM199311113292004.
  108. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355 (9200):253–9.
  109. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H et al. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. New England Journal of Medicine. 2001;345 (12):861–9. DOI:10.1056/NEJMoa011161.
  110. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau J-L et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med. 2003;138 (7):542–9.
  111. Savard LA, Thompson DR, Clark AM. A meta-review of evidence on heart failure disease management programs: the challenges of describing and synthesizing evidence on complex interventions. Trials. 2011;12 (1). DOI:10.1186/1745‑6215‑12‑194.
  112. Мареев В. Ю., Беграмбекова Ю. Л., Даниелян М. О., Агеев Ф. Т., Гиляревский С. Р., Беленков Ю. Н. и др. Какие вопросы задаются и на какие вопросы способны ответить исследования по немедикаментозному лечению пациентов с сердечной недостаточностью. Уроки исследования ШАНС. Журнал Сердечная Недостаточность. 2014;15 (6):383–96 [Mareev V. Yu., Begrambekova Yu. L., Danielyan M. O., Ageev F. T., Gilyarevskij S. R., Belenkov Yu. N. i dr. Kakie voprosy` zadayutsya i na kakie voprosy` sposobny` otvetit` issledovaniya po nemedikamentoznomu lecheniyu paczientov s serdechnoj nedostatochnost`yu. Uroki issledovaniya ShANS. Zhurnal Serdechnaya Nedostatochnost`. 2014;15 (6):383–96].
  113. Ekman I, Andersson B, Ehnfors M, Matejka G, Persson B, Fagerberg B. Feasibility of a nurse-monitored, outpatient-care programme for elderly patients with moderate-to-severe, chronic heart failure. Eur Heart J. 1998;19 (8):1254–60.
  114. Jaarsma T. Effects of education and support on self-care and resource utilization in patients with heart failure. European Heart Journal. 1999;20 (9):673–82. DOI:10.1053/euhj.1998.1341.
  115. Blue L, Lang E, McMurray JJ, Davie AP, McDonagh TA, Murdoch DR et al. Randomised controlled trial of specialist nurse intervention in heart failure. BMJ. 2001;323 (7315):715–8.
  116. McDonald K, Ledwidge M, Cahill J, Quigley P, Maurer B, Travers B et al. Heart failure management: Multidisciplinary care has intrinsic benefit above the optimization of medical care. Journal of Cardiac Failure. 2002;8 (3):142–8. DOI:10.1054/jcaf.2002.124340.
  117. Krumholz HM, Amatruda J, Smith GL, Mattera JA, Roumanis SA, Radford MJ et al. Randomized trial of an education and support intervention to prevent readmission of patients with heart failure. J Am Coll Cardiol. 2002;39 (1):83–9.
  118. Stewart S, Pearson S, Horowitz JD. Effects of a home-based intervention among patients with congestive heart failure discharged from acute hospital care. Arch Intern Med. 1998;158 (10):1067–72.
  119. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. American Heart Journal. 2007;154 (2):260–6. DOI:10.1016/j.ahj.2007.01.041.
  120. Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Leiro MC, Drozdz J et al. EURObservational Research Programme: regional differences and 1‑year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). European Journal of Heart Failure. 2013;15 (7):808–17. DOI:10.1093/eurjhf/hft050.
  121. Мареев В. Ю., Арутюнов Г. П., Асташкин Е. И., Вёрткин А. Л., Глезер М. Г., Лопатин Ю. М. и др. Острая декомпенсированная сердечная недостаточность. Согласованная позиция российских экспертов – 2014. Журнал Сердечная Недостаточность. 2014;15 (5):321–36 [Mareev V. Yu., Arutyunov G. P., Astashkin E. I., Vyortkin A. L., Glezer M. G., Lopatin Yu. M. i dr. Ostraya dekompensirovannaya serdechnaya nedostatochnost`. Soglasovannaya pozicziya rossijskix e`kspertov – 2014. Zhurnal Serdechnaya Nedostatochnost`. 2014;15 (5):321–36].
  122. Арутюнов А. Г., Драгунов Д. О., Арутюнов Г. П., Рылова А. К., Пашкевич Д. Д., Витер К. В. и др. Первое открытое исследование синдрома острой декомпенсации сердечной недостаточности и сопутствующих заболеваний в Российской Федерации. Независимый регистр ОРАКУЛ–РФ. Кардиология. 2015;55 (5):12–21 [Arutyunov A. G., Dragunov D. O., Arutyunov G. P., Ry`lova A. K., Pashkevich D. D., Viter K. V. i dr. Pervoe otkry`toe issledovanie sindroma ostroj dekompensaczii serdechnoj nedostatochnosti i soputstvuyushhix zabolevanij v Rossijskoj Federaczii. Nezavisimy`j registr ORAKUL–RF. Kardiologiya. 2015;55 (5):12–21].
  123. Chakko S, Woska D, Martinez H, de Marchena E, Futterman L, Kessler KM et al. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. Am J Med. 1991;90 (3):353–9.
  124. Wang CS. Does This Dyspneic Patient in the Emergency Department Have Congestive Heart Failure? JAMA. 2005;294 (15):1944. DOI:10.1001/jama.294.15.1944.
  125. Sarasin FP. Acute dyspnea: what is the diagnostic role of B-type natriuretic peptide? Rev Med Suisse. 2005;1 (29):1888–91.
  126. Zaphiriou A, Robb S, Murray-Thomas T, Mendez G, Fox K, McDonagh T et al. The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: Results of the UK natriuretic peptide study. European Journal of Heart Failure. 2005;7 (4):537–41. DOI:10.1016/j.ejheart.2005.01.022.
  127. Martindale JL, Wakai A, Collins SP, Levy PD, Diercks D, Hiestand BC et al. Diagnosing Acute Heart Failure in the Emergency Department: A Systematic Review and Meta-analysis. Carpenter C. Academic Emergency Medicine. 2016;23 (3):223–42. DOI:10.1111/acem.12878.
  128. Forrester JS, Diamond GA, Swan HJ. Correlative classification of clinical and hemodynamic function after acute myocardial infarction. Am J Cardiol. 1977;39 (2):137–45.
  129. Nohria A, Mielniczuk LM, Warner Stevenson L. Evaluation and Monitoring of Patients with Acute Heart Failure Syndromes. The American Journal of Cardiology. 2005;96 (6):32–40. DOI:10.1016/j.amjcard.2005.07.019.
  130. Park JH, Balmain S, Berry C, Morton JJ, McMurray JJV. Potentially detrimental cardiovascular effects of oxygen in patients with chro­nic left ventricular systolic dysfunction. Heart. 2010;96 (7):533–8. DOI:10.1136/hrt.2009.175257.
  131. Rawles JM, Kenmure AC. Controlled trial of oxygen in uncomplicated myocardial infarction. Br Med J. 1976;1 (6018):1121–3.
  132. Vital FMR, Ladeira MT, Atallah AN. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema. Cochrane Database Syst Rev. 2013; (5):CD005351. DOI:10.1002/14651858. CD005351.pub3.
  133. Park M, Sangean MC, Volpe M de S, Feltrim MIZ, Nozawa E, Leite PF et al. Randomized, prospective trial of oxygen, continuous positive airway pressure, and bilevel positive airway pressure by face mask in acute cardiogenic pulmonary edema. Crit Care Med. 2004;32 (12):2407–15.
  134. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR et al. Diuretic Strategies in Patients with Acute Decompensated Heart Failure. New England Journal of Medicine. 2011;364 (9):797–805. DOI:10.1056/NEJMoa1005419.
  135. Martens P, Nijst P, Mullens W. Current Approach to Decongestive Therapy in Acute Heart Failure. Current Heart Failure Reports. 2015;12 (6):367–78. DOI:10.1007/s11897‑015‑0273‑5.
  136. van Vliet A, Donker AJM, Nauta JJP, Verheugt FWA. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. The American Journal of Cardiology. 1993;71 (3):A21–8. DOI:10.1016/0002–9149 (93) 90241–4.
  137. Butler J, Hernandez AF, Anstrom KJ, Kalogeropoulos A, Redfield MM, Konstam MA et al. Rationale and Design of the ATHENA-HF Trial. JACC: Heart Failure. 2016;4 (9):726–35. DOI:10.1016/j.jchf.2016.06.003.
  138. Knauf H, Mutschler E. Sequential nephron blockade breaks resistance to diuretics in edematous states. J Cardiovasc Pharmacol. 1997;29 (3):367–72.
  139. Bart BA, Goldsmith SR, Lee KL, Givertz MM, O’Connor CM, Bull DA et al. Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome. New England Journal of Medicine. 2012;367 (24):2296–304. DOI:10.1056/NEJMoa1210357.
  140. Farag M, Shoaib A, Gorog DA. Nitrates for the Management of Acute Heart Failure Syndromes, A Systematic Review. Journal of Cardiovascular Pharmacology and Therapeutics. 2017;22 (1):20–7. DOI:10.1177/1074248416644345.
  141. Wakai A, McCabe A, Kidney R, Brooks SC, Seupaul RA, Diercks DB et al. Nitrates for acute heart failure syndromes. Cochrane Database of Systematic Reviews. 2013;6 (8):CD005151. DOI:10.1002/14651858. CD005151.pub2.
  142. Cotter G, Metzkor E, Kaluski E, Faigenberg Z, Miller R, Simovitz A et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. The Lancet. 1998;351 (9100):389–93. DOI:10.1016/S0140–6736 (97) 08417–1.
  143. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. The Lancet. 2013;381 (9860):29–39. DOI:10.1016/S0140–6736 (12) 61855–8.
  144. Belletti A, Castro ML, Silvetti S, Greco T, Biondi-Zoccai G, Pasin L et al. The Effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials. Myles PS. British Journal of Anaesthesia. 2015;115 (5):656–75. DOI:10.1093/bja/aev284.
  145. Elkayam U, Tasissa G, Binanay C, Stevenson LW, Gheorghiade M, Warnica JW et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. American Heart Journal. 2007;153 (1):98–104. DOI:10.1016/j.ahj.2006.09.005.
  146. Mebazaa A, Parissis J, Porcher R, Gayat E, Nikolaou M, Boas FV et al. Short-term survival by treatment among patients hospita­lized with acute heart failure: the global ALARM-HF registry using propensity scoring methods. Intensive Care Medicine. 2011;37 (2):290–301. DOI:10.1007/s00134‑010‑2073‑4.
  147. Kivikko M, Pollesello P, Tarvasmäki T, Sarapohja T, Nieminen MS, Harjola V-P. Effect of baseline characteristics on morta­lity in the SURVIVE trial on the effect of levosimendan vs dobutamine in acute heart failure: Sub-analysis of the Finnish patients. International Journal of Cardiology. 2016;215:26–31. DOI:10.1016/j.ijcard.2016.04.064.
  148. The Consensus Trial Study Group*. Effects of Enalapril on Mortality in Severe Congestive Heart Failure. New England Journal of Medicine. 1987;316 (23):1429–35. DOI:10.1056/NEJM198706043162301.
  149. Jondeau G, Neuder Y, Eicher J-C, Jourdain P, Fauveau E, Galinier M et al. B-CONVINCED: Beta-blocker CONtinuation Vs. INterrup­tion in patients with Congestive heart failure hospitalizED for a decompensation episode. European Heart Journal. 2009;30 (18):2186–92. DOI:10.1093/eurheartj/ehp323
  150. Packer M, Fowler MB, Roecker EB, Coats AJS, Katus HA, Krum H et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective rando­mized cumulative survival (COPERNICUS) study. Circulation. 2002;106 (17):2194–9.
  151. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353 (9146):9–13.
  152. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353 (9169):2001–7.
  153. Borer JS, Bohm M, Ford I, Komajda M, Tavazzi L, Sendon JL et al. Effect of ivabradine on recurrent hospitalization for worse­ning heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal. 2012;33 (22):2813–20. DOI:10.1093/eurheartj/ehs259.
  154. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J. High Prevalence of Renal Dysfunction and Its Impact on Outcome in 118,465 Patients Hospitalized With Acute Decompensated Heart Failure: A Report From the ADHERE Database. Journal of Cardiac Failure. 2007;13 (6):422–30. DOI:10.1016/j.cardfail.2007.03.011.
  155. Campbell RC, Sui X, Filippatos G, Love TE, Wahle C, Sanders PW et al. Association of chronic kidney disease with outcomes in chro­nic heart failure: a propensity-matched study. Nephrology Dialysis Transplantation. 2008;24 (1):186–93. DOI:10.1093/ndt/gfn445.
  156. Hillege HL. Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure. Circulation. 2006;113 (5):671–8. DOI:10.1161/CIRCULATIONAHA.105.580506.
  157. Gigante A, Liberatori M, Gasperini ML, Sardo L, Di Mario F, Dorelli B et al. Prevalence and Clinical Features of Patients with the Cardiorenal Syndrome Admitted to an Internal Medicine Ward. Cardiorenal Medicine. 2014;4 (2):88–94. DOI:10.1159/000362566.
  158. Clementi A, Virzì GM, Goh CY, Cruz DN, Granata A, Vescovo G et al. Cardiorenal Syndrome Type 4: A Review. Cardiorenal Medicine. 2013;3 (1):63–70. DOI:10.1159/000350397.
  159. Damman K, Valente MAE, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. European Heart Journal. 2014;35 (7):455–69. DOI:10.1093/eurheartj/eht386.
  160. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney inter. 2012; (2):1–138.
  161. Adams KF, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). American Heart Journal. 2005;149 (2):209–16. DOI:10.1016/j.ahj.2004.08.005.
  162. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH et al. Characteristics, Treatments, and Outcomes of Patients With Preserved Systolic Function Hospitalized for Heart Failure. Journal of the American College of Cardiology. 2007;50 (8):768–77. DOI:10.1016/j.jacc.2007.04.064.
  163. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352 (9131):854–65.
  164. Masoudi FA. Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study. Circulation. 2005;111 (5):583–90. DOI:10.1161/01. CIR.0000154542.13412. B1.
  165. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Trials. JAMA. 2007;298 (10):1180. DOI:10.1001/jama.298.10.1180.
  166. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine. 2013;369 (14):1317–26. DOI:10.1056/NEJMoa1307684.
  167. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL et al. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. New England Journal of Medicine. 2013;369 (14):1327–35. DOI:10.1056/NEJMoa1305889.
  168. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2015;373 (3):232–42. DOI:10.1056/NEJMoa1501352.
  169. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. New England Journal of Medicine. 2015;373 (23):2247–57. DOI:10.1056/NEJMoa1509225.
  170. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016;375 (19):1834–44. DOI:10.1056/NEJMoa1607141.
  171. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015;373 (22):2117–28. DOI:10.1056/NEJMoa1504720.
  172. Sonesson C, Johansson PA, Johnsson E, Gause-Nilsson I. Cardio­vascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovascular Diabetology. 2016;15 (1). DOI:10.1186/s12933‑016‑0356‑y.
  173. Authors/Task Force Members, Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal. 2008;29 (19):2388–442. DOI:10.1093/eurheartj/ehn309.
  174. Barzilay J. Risk and impact of incident glucose disorders in hypertensive older adults treated with an ace inhibitor, a diuretic, or a calcium channel blocker: a report from the allhat trial. American Journal of Hypertension. 2004;17 (5):S1. DOI:10.1016/j.amjhyper.2004.03.002.
  175. Gottlieb SS, McCarter RJ, Vogel RA. Effect of Beta-Blockade on Mortality among High-Risk and Low-Risk Patients after Myocardial Infarction. New England Journal of Medicine. 1998;339 (8):489–97. DOI:10.1056/NEJM199808203390801.
  176. Heinemann L, Heise T, Ampudia J, Sawicki P, Sindelka G, Brunner G et al. Four week administration of an ACE inhibitor and a cardioselective beta-blocker in healthy volunteers: no influence on insulin sensitivity. Eur J Clin Invest. 1995;25 (8):595–600.
  177. Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med. 1997;126 (12):955–9.
  178. Мареев В. Ю., Даниелян М. О., Осмаловская Ю. Ф., Агеев Ф. Т., Серединина Е. М., Жубрина Е. С. и др. НЕбиволол против МЕтопролола: сравнительное рандомиЗированное Иссле­До­вАние у больных Хронической Сердечной Недоста­точностью (НЕМЕЗИДА–ХСН). Журнал Сердечная Недоста­точность. 14 (2):63–74 [Mareev V. Yu., Danielyan M. O., Osmalovskaya Yu. F., Ageev F. T., Seredinina E. M., Zhubrina E. S. i dr. NEbivolol protiv MEtoprolola: sravnitel`noe randomiZirovannoe IssleDovAnie u bol`ny`x Xronicheskoj Serdechnoj Nedostatochnost`yu (NEMEZIDA–XSN). Zhurnal Serdechnaya Nedostatochnost`. 14 (2):63–74].
  179. Torp-Pedersen C, Metra M, Charlesworth A, Spark P, Lukas MA, Poole-Wilson PA et al. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart. 2007;93 (8):968–73. DOI:10.1136/hrt.2006.092379.
  180. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA et al. Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension: A Randomized Controlled Trial. JAMA. 2004;292 (18):2227. DOI:10.1001/jama.292.18.2227.
  181. Hawkins NM, Huang Z, Pieper KS, Solomon SD, Kober L, Velazquez EJ et al. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). European Journal of Heart Failure. 2009;11 (3):292–8. DOI:10.1093/eurjhf/hfp001.
  182. Apostolovic S, Jankovic-Tomasevic R, Salinger-Martinovic S, Djordjevic-Radojkovic D, Stanojevic D, Pavlovic M et al. Frequency and significance of unrecognized chronic obstructive pulmonary disease in elderly patients with stable heart failure. Aging Clinical and Experimental Research. 2011; (5–6). DOI:10.3275/7291.
  183. Mentz RJ, Schulte PJ, Fleg JL, Fiuzat M, Kraus WE, Piña IL et al. Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: Findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION). American Heart Journal. 2013;165 (2):193–9. DOI:10.1016/j.ahj.2012.10.029.
  184. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and Therapeutic Challenges in Patients With Coexistent Chronic Obstructive Pulmonary Disease and Chronic Heart Failure. Journal of the American College of Cardiology. 2007;49 (2):171–80. DOI:10.1016/j.jacc.2006.08.046.
  185. Zeng Q, Jiang S. Update in diagnosis and therapy of coexistent chronic obstructive pulmonary disease and chronic heart fai­lure. J Thorac Dis. 2012;4 (3):310–5. DOI:10.3978/j.issn.2072–1439.2012.01.09.
  186. Чучалин А. Г. Хроническая обструктивная болезнь легких и сопутствующие заболевания. Терапевтический архив. 2013;85 (8):43–8 [Chuchalin A. G. Xronicheskaya obstruktivnaya bolezn` legkix i soputstvuyushhie zabolevaniya. Terapevticheskij arxiv. 2013;85 (8):43–8].
  187. Mancini GBJ, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of Morbidity and Mortality by Statins, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers in Patients With Chronic Obstructive Pulmonary Disease. Journal of the American College of Cardiology. 2006;47 (12):2554–60. DOI:10.1016/j.jacc.2006.04.039.
  188. Mortensen EM, Copeland LA, Pugh MJV, Restrepo MI, de Molina RM, Nakashima B et al. Impact of statins and ACE inhibi­tors on mortality after COPD exacerbations. Respiratory Research. 2009;10 (1). DOI:10.1186/1465‑9921‑10‑45.
  189. Федотов П. А., Ситникова М. Ю., Сафьянова Н. В.,_ Шапорова Н. Л. Хроническая сердечная недостаточность ишемического генеза и хроническая обструктивная болезнь легких: возможности комбинированной терапии, включающей небиволол. Клиницист. 2013; (3–4):40–7 [Fedotov P. A., Sitnikova M. Yu., Saf`yanova N. V., Shaporova N. L. Xronicheskaya serdechnaya nedostatochnost` ishemicheskogo geneza i xronicheskaya obstruktivnaya bolezn` legkix: vozmozhnosti kombinirovannoj terapii, vklyuchayushhej nebivolol. Kliniczist. 2013; (3–4):40–7].
  190. Stefan MS, Rothberg MB, Priya A, Pekow PS, Au DH, Lindenauer PK. Association between β-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax. 2012;67 (11):977–84. DOI:10.1136/thoraxjnl-2012–201945.
  191. Etminan M, Jafari S, Carleton B, FitzGerald JM. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulmonary Medicine. 2012;12 (1). DOI:10.1186/1471‑2466‑12‑48.
  192. Rutten FH. β-Blockers May Reduce Mortality and Risk of Exacer­ba­tions in Patients With Chronic Obstructive Pulmonary Disease. Archives of Internal Medicine. 2010;170 (10):880–7. DOI:10.1001/archinternmed.2010.112.
  193. Du Q, Sun Y, Ding N, Lu L, Chen Y. Beta-Blockers Reduced the Risk of Mortality and Exacerbation in Patients with COPD: A Meta-Analysis of Observational Studies. Chalmers JD. PLoS ONE. 2014;9 (11):e113048. DOI:10.1371/journal.pone.0113048.
  194. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in Heart Failure. Journal of the American College of Cardiology. 2006;48 (8):1527–37. DOI:10.1016/j.jacc.2006.06.055.
  195. Оганов Р. Г., Ольбинская Л. И., Смулевич А. Б., Вейн А. М., Дробижев М. Ю., Шальнова С. А. и др. Депрессии и расстройства депрессивного спектра в общемедицинской практике. Результаты программы КОМПАС. Кардиология. 2004;44 (1):48 [Oganov R. G., Ol`binskaya L. I., Smulevich A. B., Vejn A. M., Drobizhev M. Yu., Shal`nova S. A. i dr. Depressii i rasstrojstva depressivnogo spektra v obshhemediczinskoj praktike. Rezul`taty` programmy` KOMPAS. Kardiologiya. 2004;44 (1):48].
  196. Беграмбекова Ю. Л.,_Дробижев М. Ю.,_Мареев В. Ю., Кикта С. В. Можно ли сказать что‑то новое о депрессиях у больных хронической сердечной недостаточностью? Журнал Сердечная Недостаточность. 2015;16 (6):360–7. DOI:10.18087/rhfj.2015.6.2161 [Begrambekova Yu. L., Drobizhev M. Yu., Mareev V. Yu., Kikta S. V. Mozhno li skazat` chto-to novoe o depressiyax u bol`ny`x xronicheskoj serdechnoj nedostatochnost`yu? Zhurnal Serdechnaya Nedostatochnost`. 2015;16 (6):360–7. DOI:10.18087/rhfj.2015.6.2161].
  197. Васюк Ю. А., Довженко Т. В. Хроническая сердечная недостаточность и расстройства депрессивного спектра. Журнал Сердечная Недостаточность. 2009;10 (6):342–8 [Vasyuk Yu. A., Dovzhenko T. V. Xronicheskaya serdechnaya nedostatochnost` i rasstrojstva depressivnogo spektra. Zhurnal Serdechnaya Nedostatochnost`. 2009;10 (6):342–8].
  198. Pihl E, Jacobsson A, Fridlund B, Strömberg A, Måtensson J. Depression and health-related quality of life in elderly patients suffering from heart failure and their spouses: a comparative study. European Journal of Heart Failure. 2005;7 (4):583–9. DOI:10.1016/j.ejheart.2004.07.016.
  199. Sullivan M, Simon G, Spertus J, Russo J. Depression-related costs in heart failure care. Arch Intern Med. 2002;162 (16):1860–6.
  200. Katon W, Lin EHB, Kroenke K. The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. General Hospital Psychiatry. 2007;29 (2):147–55. DOI:10.1016/j.genhosppsych.2006.11.005.
  201. Дробижев М. Ю., Беграмбекова Ю. Л., Мареев В. Ю., Кикта С. В. Влияние депрессии и тревоги на клинические исходы у больных ХСН. Журнал Сердечная Недостаточность. 2016;17 (2):91–8. DOI:10.18087/rhfj.2016.2.2206 [Drobizhev M. Yu., Begrambekova Yu. L., Mareev V. Yu., Kikta S. V. Vliyanie depressii i trevogi na klinicheskie isxody` u bol`ny`x XSN. Zhurnal Serdechnaya Nedostatochnost`. 2016;17 (2):91–8. DOI:10.18087/rhfj.2016.2.2206].
  202. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160 (14):2101–7.
  203. Lahlou-Laforêt K, Ledru F, Niarra R, Consoli SM. Validity of Beck Depression Inventory for the assessment of depressive mood in chronic heart failure patients. Journal of Affective Disorders. 2015;184:256–60. DOI:10.1016/j.jad.2015.05.056.
  204. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002;52 (2):69–77.
  205. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67 (6):361–70.
  206. Андрющенко А. В., Дробижев М. Ю., Добровольский А. В. Сравнительная оценка шкал CES-D, BDI и HADS (d) в диагностике депрессий в общемедицинской практике. Журнал неврологии и психиатрии им СС Корсакова. 2003; (5):11–8 [Andryushhenko A. V., Drobizhev M. Yu., Dobrovol`skij A. V. Sravnitel`naya oczenka shkal CES-D, BDI i HADS (d) v diagnostike depressij v obshhemediczinskoj praktike. Zhurnal nevrologii i psixiatrii im SS Korsakova. 2003; (5):11–8].
  207. Gelbrich G, Störk S, Kreißl-Kemmer S, Faller H, Prettin C, Heuschmann PU et al. Effects of structured heart failure disease management on mortality and morbidity depend on patients’ mood: results from the Interdisciplinary Network for Heart Failure Study: Effects of structured HF management depend on patients’ mood. European Journal of Heart Failure. 2014;16 (10):1133–41. DOI:10.1002/ejhf.150.
  208. de la Porte PWFB-A, Lok DJA, van Veldhuisen DJ, van Wijngaarden J, Cornel JH, Zuithoff NPA et al. Added value of a physician-and-nurse-directed heart failure clinic: results from the Deventer – Alkmaar heart failure study. Heart. 2007;93 (7):819–25. DOI:10.1136/hrt.2006.095810.
  209. Clark AM, Thompson DR. The future of management programmes for heart failure. The Lancet. 2008;372 (9641):784–6. DOI:10.1016/S0140–6736 (08) 61317–3.
  210. Беленков Ю. Н., Агеев Ф. Т., Банщиков Г. Т., Волкова Е. Г., Гиляревский С. Р., Донова И. Г. и др. Влияние специализированных форм активного амбулаторного ведения на функциональный статус, качество жизни и показатели гемодинамики больных с выраженной сердечной недостаточностью. Результаты Российской программы «ШАНС». Журнал Сердечная Недостаточность. 2007;8 (3):112–6 [Belenkov Yu. N., Ageev F. T., Banshhikov G. T., Volkova E. G., Gilyarevskij S. R., Donova I. G. i dr. Vliyanie speczializirovanny`x form aktivnogo ambulatornogo vedeniya na funkczional`ny`j status, kachestvo zhizni i pokazateli gemodinamiki bol`ny`x s vy`razhennoj serdechnoj nedostatochnost`yu. Rezul`taty` Rossijskoj programmy` «ShANS». Zhurnal Serdechnaya Nedostatochnost`. 2007;8 (3):112–6].
  211. Беграмбекова Ю. Л., Мареев В. Ю., Дробижев М. Ю. Школы для пациентов с сердечной недостаточностью. Есть ли ШАНС повлиять на депрессию и тревогу? Вторичный (Post-hoc) анализ исследования ШАНС (Школа и Амбулаторное Наблюдение больных Сердечной недостаточностью). Журнал Сердечная Недостаточность. 2016;17 (6):433–42. DOI:10.18087/rhfj.2016.6.2281 [Begrambekova Yu. L., Mareev V. Yu., Drobizhev M. Yu. Shkoly` dlya paczientov s serdechnoj nedostatochnost`yu. Est` li ShANS povliyat` na depressiyu i trevogu? Vtorichny`j (Post-hoc) analiz issledovaniya ShANS (Shkola i Ambulatornoe Nablyudenie bol`ny`x Serdechnoj nedostatochnost`yu). Zhurnal Serdechnaya Nedostatochnost`. 2016;17 (6):433–42. DOI:10.18087/rhfj.2016.6.2281].
  212. Dekker RL. Cognitive Therapy for Depression in Patients with Heart Failure: A Critical Review. Heart Failure Clinics. 2011;7 (1):127–41. DOI:10.1016/j.hfc.2010.10.001.
  213. Tu R-H, Zeng Z-Y, Zhong G-Q, Wu W-F, Lu Y-J, Bo Z-D et al. Effects of exercise training on depression in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials: Effects of exercise training on depression in HF: a systematic review. European Journal of Heart Failure. 2014;16 (7):749–57. DOI:10.1002/ejhf.101.
  214. Blumenthal JA, Babyak MA, O’Connor C, Keteyian S, Landzberg J, Howlett J et al. Effects of Exercise Training on Depressive Symptoms in Patients With Chronic Heart Failure: The HF-ACTION Randomized Trial. JAMA. 2012;308 (5):465–74. DOI:10.1001/jama.2012.8720.
  215. Glassman AH. Cardiovascular Effects of Tricyclic Antidepressants. Annual Review of Medicine. 1984;35 (1):503–11. DOI:10.1146/annurev.me.35.020184.002443.
  216. O’Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD et al. Safety and Efficacy of Sertraline for Depression in Patients With Heart Failure. Journal of the American College of Cardiology. 2010;56 (9):692–9. DOI:10.1016/j.jacc.2010.03.068.
  217. Angermann CE, Gelbrich G, Störk S, Gunold H, Edelmann F, Wachter R et al. Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. JAMA. 2016;315 (24):2683. DOI:10.1001/jama.2016.7635.
  218. Faller H, Störk S, Gelbrich G, Schowalter M, Ertl G, Angermann CE. Depressive symptoms in heart failure: Independent prognostic factor or marker of functional status? Journal of Psychosomatic Research. 2015;78 (6):569–72. DOI:10.1016/j.jpsychores.2015.02.015.
  219. Goldberg RJ, Capone RJ, Hunt JD. Cardiac complications follo­wing tricyclic antidepressant overdose. Issues for monitoring policy. JAMA. 1985;254 (13):1772–5.
  220. Pacher P, Ungvari Z, Nanasi PP, Furst S, Kecskemeti V. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? Curr Med Chem. 1999;6 (6):469–80.
  221. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302 (1):381–9.
  222. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5‑HT1A receptor. Eur J Pharmacol. 2002;441 (3):137–40.
  223. Taylor DM. Aripiprazole: a review of its pharmacology and clinical use. Int J Clin Pract. 2003;57 (1):49–54.
Mareev V. Yu., Fomin I. V., Ageev F. T., Arutyunov G. P., Begrambekova Yu. L., Belenkov Yu. N. et al. Clinical guidelines. Chronic heart failure (CHF). Russian Heart Failure Journal. 2017;18 (1):3–40

To access this material please log in or register

Register Authorize
Ru En